Fibroepithelial lesions; The WHO spectrum

Semin Diagn Pathol. 2017 Sep;34(5):438-452. doi: 10.1053/j.semdp.2017.05.006. Epub 2017 May 28.

Abstract

Fibroepithelial lesions of the breast comprise a morphologically and biologically heterogeneous group of biphasic tumors with epithelial and stromal components that demonstrate widely variable clinical behavior. Fibroadenomas are common benign tumors with a number of histologic variants, most of which pose no diagnostic challenge. Cellular and juvenile fibroadenomas can have overlapping features with phyllodes tumors and should be recognized. Phyllodes tumors constitute a spectrum of lesions with varying clinical behavior and are graded as benign, borderline or malignant based on a set of histologic features according to recommendations by the World Health Organization (WHO). Recent developments have significantly expanded our understanding of the pathogenesis of fibroepithelial lesions, highlighting fibroadenomas as true neoplasms and underscoring a commonality with phyllodes tumors in the form of recurrent MED12 exon 2 mutations. In addition, sequencing studies have elucidated pathways associated with phyllodes tumor progression. Accurate diagnosis and grading of phyllodes tumors are important for patient management and prognosis, as grade broadly correlates with increasing local recurrence risk, and essentially only malignant tumors metastasize. However, classification of fibroepithelial lesions in many cases remains challenging on both core biopsy and excision specimens. A commonly encountered problem at the benign end of the spectrum is the distinction of benign phyllodes tumor from cellular fibroadenoma, which is largely due to the subjective nature of histologic features used in diagnosis and histologic overlap between lesions. Grading is further complicated by the requirement to integrate multiple subjective and ill-defined parameters. On the opposite end of the histologic spectrum, malignant phyllodes tumors must be distinguished from more common metaplastic carcinomas and from primary or metastatic sarcomas, which can be especially difficult in core biopsies. Immunohistochemistry can be useful in the differential diagnosis but should be interpreted with attention to caveats. This review provides an overview and update on the spectrum of fibroepithelial lesions, with special emphasis on common problems and practical issues in diagnosis.

Keywords: Breast; Fibroadenoma; Fibroepithelial; Phyllodes; Sarcoma.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Biopsy
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology*
  • Diagnosis, Differential
  • Female
  • Fibroadenoma / chemistry
  • Fibroadenoma / genetics
  • Fibroadenoma / pathology
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry
  • Molecular Diagnostic Techniques
  • Neoplasm Grading
  • Neoplasms, Fibroepithelial / chemistry
  • Neoplasms, Fibroepithelial / genetics
  • Neoplasms, Fibroepithelial / pathology*
  • Phenotype
  • Phyllodes Tumor / chemistry
  • Phyllodes Tumor / genetics
  • Phyllodes Tumor / pathology*
  • Predictive Value of Tests
  • World Health Organization*

Substances

  • Biomarkers, Tumor